Cross-resistance and drug sequence in prostate cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cross-resistance and drug sequence in prostate cancer

Published:2021-05 Issue: Volume:56 Page:100761
ISSN:1368-7646
Container-title:Drug Resistance Updates
language:en
Short-container-title:Drug Resistance Updates

Author:

Buck Stefan A.J.,Koolen Stijn L.W.,Mathijssen Ron H.J.,de Wit Ronald,van Soest Robert J.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Cancer Research,Pharmacology,Oncology

Reference100 articles.

1. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies;Al Nakouzi;Eur. Urol.,2015

2. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer;Antonarakis;JAMA Oncol.,2015

3. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer;Antonarakis;N. Engl. J. Med.,2014

4. Clinical significance of androgen receptor splice Variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide;Antonarakis;J. Clin. Oncol.,2017

5. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade;Arora;Cell,2013

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Treatment Patterns in Patients With Metastatic Castration-Resistant Prostate Cancer in Greece: The PROSPECT Study;Clinical Genitourinary Cancer;2024-12

2. SLC4A4 is a novel driver of enzalutamide resistance in prostate cancer;Cancer Letters;2024-08

3. Key genes and molecular mechanisms related to Paclitaxel Resistance;Cancer Cell International;2024-07-13

4. Apalutamide and Goserelin for Androgen Receptor–Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU;Clinical Cancer Research;2024-06-28

5. The interplay between autophagy and ferroptosis presents a novel conceptual therapeutic framework for neuroendocrine prostate cancer;Pharmacological Research;2024-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3